[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354446-105":59,"doc-detail-354446-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","membrane-fusion-mediated-cytosolic-delivery-of-threose-nucleic-acids-via-homotypic-nanoparticles-overcomes-drug-resistance-in-triple-negative-breast-cancer-research-article","Membrane Fusion-Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple-Negative Breast Cancer - Research Article","","Triple-negative breast cancer (TNBC) remains lethal due to aggressive molecular heterogeneity and drug resistance. A biomimetic nanoplatform (PLL/TNAAKT2 @CM NPs) integrates biostable threose nucleic acid (TNA) with donor-derived cell membrane cloaks for subtype-specific therapy. Homotypic affinity and rapid membrane-fusion enable direct cytosolic delivery, achieving robust AKT2 silencing with ~70% protein knockdown and improved performance versus conventional reagents. In drug-resistant xenografts, systemic dosing yields superior tumor accumulation, AKT2 knockdown, and tumor regression through the p21/Caspase-3 apoptotic axis without systemic toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/membrane-fusion-mediated-cytosolic-delivery-of-threose-nucleic-acids-via-homotypic-nanoparticles-overcomes-drug-resistance-in-triple-negative-breast-cancer-research-article/354446/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/membrane-fusion-mediated-cytosolic-delivery-of-threose-nucleic-acids-via-homotypic-nanoparticles-overcomes-drug-resistance-in-triple-negative-breast-cancer-research-article/354446.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in triple-negative breast cancer?","Question",{"text":112,"@type":113},"The study targets TNBC lethality driven by molecular heterogeneity and drug resistance, where limited options lead to relapse and mortality.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the PLL/TNAAKT2 @CM nanoparticle design work?",{"text":117,"@type":113},"It complexes TNAAKT2 antisense oligonucleotides with poly-L-lysine (PLL) and coats them with donor-derived cell membrane membranes to promote homotypic affinity and targeted delivery.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism enables cytosolic delivery and improved gene silencing?",{"text":121,"@type":113},"The nanoparticles internalize through rapid membrane fusion, bypassing endosomal entrapment for direct cytosolic delivery, leading to strong AKT2 knockdown and antitumor effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354446,1790623985,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Advanced Science  \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nMembrane Fusion-Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple-Negative Breast Cancer  \nWei Zheng1  Tristan Juin Han Chang1  Xinchao Li1  Zhongqi Zhou1  Chung Tin2  Kenward Vong3  Pierre Karam4  Pik Kwan Lo1, 5, 6  \n1 Department of Chemistry and State Key Laboratory of Marine Environmental Health, Kowloon Tong, Hong Kong, China  2 Department of Biomedical Engineering, City University of Hong Kong, Kowloon Tong, Hong Kong, China  3 Department of Chemistry, The Hong Kong University of Science and Technology, Kowloon, Hong Kong, China  4 Department of Chemistry, American University of Beirut, Beirut, Lebanon  5 City University of Hong Kong Chengdu Research Institute, Chengdu, China  6 Key Laboratory of Biochip Technology, Biotech and Health Care, Shenzhen Research Institute of City University of Hong Kong, Shenzhen, China  \nCorrespondence: Pik Kwan Lo ([peggylo@cityu.edu.hk](peggylo@cityu.edu.hk))  \nReceived: 13 March 2026  Revised: 15 May 2026  Accepted: 3 June 2026  \nKeywords: biomimetic | drug resistance | homotypic | membrane fusion | TNA  \nABSTRACT  \nTriple-negative breast cancer (TNBC) remains lethal due to its aggressive molecular heterogeneity and drug resistance. We report a biomimetic nanoplatform (PLL/TNAAKT2 @CM NPs) integrating biostable threose nucleic acid (TNA) with a donor-derived cell membranes (CMs)“cloak” for subtype-specific therapy. By complexing TNAAKT2 antisense oligonucleotides with poly-L-lysine (PLL) and coating them with TNBS-subtype membranes (MDA-MB-468 or MDA-MB-231), we achieve potent homotypic affinity. PLL/TNAAKT2 @468CM NPs exhibited significant enhanced uptake in donor-matched basal-like 1 cells compared to heterotypic TNBC, non-TNBC and normal epithelial cells. Mechanistically, these nanoparticles internalize via a rapid membrane-fusion, bypassing endosomal entrapment for direct cytosolic delivery. This facilitates robust silencing of the AKT2 oncogene, achieving a ∼70% protein knockdown and outperforming conventional transfection reagents. In a drug-resistant MDA-MB-468 xenografts, systemic administration led to superior tumor accumulation, effective AKT2 knockdown, and significant tumor regression via thep21/Caspase-3 apoptotic axis, without systemic toxicity. This versatile “plug-and-play” strategy addresses tumor heterogeneity and endosomal sequestration, providing a transformative paradigm for targeted nucleic acid delivery in refractory cancers.  \n1  Introduction  \nTriple-negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer that accounts for 15%–20% of all diagnosed cases. It is defined by its negative status for expression of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1] . Compared with other breast cancer subtypes, TNBC is characterized by a high degree of malignancy and invasiveness,  \na high rate of early recurrence and visceral metastasis, and limited treatment options, collectively making it one of the most clinically aggressive breast cancer subtypes [2] .  \nThe standard treatment for TNBC typically involves surgical excision, often followed by chemotherapy and/or radiotherapy. Despite these treatments, many TNBC patients still face a high risk of relapse and mortality. This is primarily due to the limitations of traditional chemotherapy, which include limited  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH  \nAdvanced Science, 2026; 0:e76100 1 of 24  \n[https://doi.org/10.1002/advs.76100](https://doi.org/10.1002/advs.76100)  \nefficacy, severe systemic side effects, poor treatment res","cbCaigDGEmNQT2G9","https://ap.wps.com/l/cbCaigDGEmNQT2G9","pdf",6489295,24,"English","# ABSTRACT\n# 1 Introduction","[{\"question\":\"What problem does the study address in triple-negative breast cancer?\",\"answer\":\"The study targets TNBC lethality driven by molecular heterogeneity and drug resistance, where limited options lead to relapse and mortality.\"},{\"question\":\"How does the PLL/TNAAKT2 @CM nanoparticle design work?\",\"answer\":\"It complexes TNAAKT2 antisense oligonucleotides with poly-L-lysine (PLL) and coats them with donor-derived cell membrane membranes to promote homotypic affinity and targeted delivery.\"},{\"question\":\"What mechanism enables cytosolic delivery and improved gene silencing?\",\"answer\":\"The nanoparticles internalize through rapid membrane fusion, bypassing endosomal entrapment for direct cytosolic delivery, leading to strong AKT2 knockdown and antitumor effects.\"}]","Membrane Fusion-Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple-Negative Breast Cancer - Research Article | PDF",1790110679,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e4eb04cd077ac3683a952045231898a.webp",983,1283,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7094bc7117918921bb3aa3bfe3158c2e.webp",982,1281,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f21af378083c0b233d20f514c02e8eb9.webp",981,1280,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73a2b15ce3a6eebb59b45fbc2207f5be.webp",980,1279]